Perspectives
From 67% to 97%: That’s a big improvement
Point-of-sale edit upped % of Rx with <7 days supply
February 9, 2020A point-of-sale edit helped decrease large opioid supplies for new users, with a 30 percent increase in prescriptions of less than seven days supply
Evidence shows that a three-day opioid prescription is enough most of the time. The Centers for Disease Control (2016) provided these guidelines, and many states have passed laws that support them. These guidelines have worked their way into doctors’ prescribing habits, but for many, it’s a slow process. This study demonstrates how benefit design can have an immediate impact on prescribing behavior. This Blue Plan implemented a point-of-sale edit to limit new opioid prescriptions to less than seven days supply. This plan’s compliance rate jumped from 67 percent to 97 percent.
Related news
Perspectives
April 25, 2024
Clinical News: April 2024
Your monthly source for drug information highlights
Perspectives
April 25, 2024
Drug Approvals Monthly Update: April 2024
This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…
Perspectives
April 25, 2024
Drug Approvals Quarterly Update: April 2024
This wrap-up provides a review of newly approved drugs, recent drug launches, new…